Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 third-quarter results that executives said reflected “the strength of ...
The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results